Skip to main content
. 2018 Aug 3;9(60):31572–31589. doi: 10.18632/oncotarget.25803

Figure 5. FGFR1 activity promotes signals through ERK/mTor in palbociclib-resistant NSCLC cells.

Figure 5

A. Fold change in the activity of a subset of tyrosine kinases obtained from a tyrosine kinase activity array in parental H358 cells grown in the absence of palbociclib and H358-PR250 cells continuously grown in palbociclib. B. Cell cycle analysis of parental H358 and H358-PR250 cells following treatment with 100 nM PD0325901, 100 nM everolimus, 10 nM LY2874455, 10 μM erlotinib, or 2 μM LDN-211904 for 24 hours. C. Assessment of apoptosis by Annexin V staining of H358 and H358-PR250 cells treated as in (B) for 3 days. D. Colony formation assay assessing the sensitivity of H358 and H358-PR250 to LY2874455 (left panel), erlotinib (middle panel) and LDN-211904 (right panel) at the indicated doses for 14 days. E. Assessment of ERK1/2 activity by Western blot analysis of lysates obtained from H358-PR250 cells treated with DMSO or LY2874455 (LY4455), erlotinib or LDN-211904 (LDN) as in (B) for 24 hours. F. Assessment of CDK2, CDK4, CDK6, Cyclin D1 and Cyclin D3 expression in parental H358 and H358-PR250 cells treated with DMSO or 10 nM LY2874455 (LY4455) for 24 hours.